Spectrum Pharma (SPPI) – Press Releases
-
Assertio Holdings, Inc. Closes Spectrum Pharmaceuticals Transaction
-
Assertio Holdings, Inc. Announces Favorable Vote on Proposed Acquisition of Spectrum Pharmaceuticals
-
Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Spectrum Pharmaceuticals Stockholders Vote “FOR” Proposed Transaction with Assertio Holdings, Inc.
-
Spectrum Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
-
Spectrum Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Update
-
Assertio Holdings, Inc. to Acquire Spectrum Pharmaceuticals, Inc. in All Stock and CVR Transaction
-
Spectrum Pharmaceuticals Reports Fourth Quarter 2022 and Full Year 2022 Financial Results and Corporate Update
-
Spectrum Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update
-
Spectrum Pharmaceuticals Receives Permanent J-Code for ROLVEDON™ (eflapegrastim-xnst) Injection (J1449) from U.S. Centers for Medicare & Medicaid Services
-
Spectrum Pharmaceuticals Provides Update on ROLVEDON™ (eflapegrastim-xnst) Injection and Announces Unaudited Fourth Quarter 2022 Financial Results
-
Spectrum Pharmaceuticals Announces New Employment Inducement Grant for Commercial Staff
-
ROSEN, A TOP RANKED LAW FIRM, Encourages Spectrum Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action– SPPI
-
Spectrum Pharmaceuticals Announces Management Changes
-
ROSEN, A LEADING LAW FIRM, Encourages Spectrum Pharmaceuticals, Inc. Investors With Losses to Secure Counsel Before Important Deadline in First Filed Securities Class Action Initiated by the Firm– S
-
Spectrum Pharmaceuticals Announces New Employment Inducement Grants for Commercial Staff
-
National Law Firm Investigating Spectrum Pharmaceuticals, Inc. Over Alleged False/Misleading Statements Regarding New Drug Application
-
Spectrum Pharmaceuticals’ ROLVEDON™ (eflapegrastim-xnst) Injection Added to NCCN Supportive Care Guidelines in Oncology for Hematopoietic Growth Factors
-
Spectrum Pharmaceuticals Announces New Employment Inducement Grants for Commercial Staff
-
Bragar Eagel & Squire, P.C. Is Investigating Spectrum, F45 Training, PROG, and Fox and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Is Investigating GrafTech, Cantaloupe, Spectrum, and F45 Training and Encourages Investors to Contact the Firm
-
Spectrum Pharmaceuticals Receives Complete Response Letter from U.S. Food and Drug Administration for Poziotinib; Reaffirms Focus on the Commercialization of ROLVEDON™ (eflapegrastim-xnst) injection
-
Bragar Eagel & Squire, P.C. Is Investigating GrafTech, Cantaloupe, Spectrum, and F45 Training and Encourages Investors to Contact the Firm
-
Spectrum Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
-
Bragar Eagel & Squire, P.C. Is Investigating Cantaloupe, EyePoint, Spectrum, and F45 Training and Encourages Investors to Contact the Firm
-
Spectrum Pharmaceuticals to Report Third Quarter 2022 Financial Results and Provide Corporate Update
-
Bragar Eagel & Squire, P.C. Is Investigating Spectrum, F45 Training, PROG, and UiPath and Encourages Investors to Contact the Firm
-
Spectrum Pharmaceuticals Announces Commercial Availability of ROLVEDON™ (eflapegrastim-xnst) Injection
-
Bragar Eagel & Squire, P.C. Is Investigating EyePoint, Spectrum, F45, and PROG and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Is Investigating EyePoint, Spectrum, and F45 and Encourages Investors to Contact the Firm
-
Bragar Eagel & Squire, P.C. Is Investigating Cantaloupe, Compass, and Spectrum and Encourages Investors to Contact the Firm
-
Spectrum Pharmaceuticals Announces Debt Financing Agreement with SLR Capital Partners with $30 Million Funded at Closing
-
Spectrum Pharmaceuticals Provides Update on Poziotinib Following FDA Oncologic Drugs Advisory Committee Meeting
-
Spectrum Pharmaceuticals Announces Data from Poster Presentation for Poziotinib in NSCLC Patients with G778_P780dup HER2 Exon 20 Mutations at ESMO Congress 2022
-
Spectrum Pharmaceuticals Receives FDA Approval for ROLVEDON™ (eflapegrastim-xnst) Injection
-
Spectrum Pharmaceuticals Announces Poster Presentation for Poziotinib in NSCLC Patients with G778_P780dup HER2 Exon 20 Mutations at the Upcoming ESMO Congress 2022
-
Spectrum Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
-
Spectrum Pharmaceuticals to Report Second Quarter 2022 Financial Results and Provide Corporate Update
-
Spectrum Pharmaceuticals to Participate in Two Upcoming Investor Conferences
-
Spectrum Pharmaceuticals to Present Data at 2022 ASCO Highlighting the Potential Predictive Capabilities of ctDNA as a Biomarker for Poziotinib Treatment Response
-
Spectrum Pharmaceuticals to Participate in H.C. Wainwright Global Investment Conference
-
Spectrum Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
-
Spectrum Pharmaceuticals Appoints Nora E. Brennan as Chief Financial Officer
-
Spectrum Pharmaceuticals to Report First Quarter 2022 Financial Results and Provide Corporate Update
-
Spectrum Pharmaceuticals Appoints Brittany K. Bradrick to Board of Directors
-
Spectrum Pharmaceuticals Announces FDA Acceptance of BLA Resubmission for Eflapegrastim
-
Spectrum Pharmaceuticals Announces Poster Presentation at the Upcoming AACR Annual Meeting
-
Spectrum Pharmaceuticals Reports Fourth Quarter 2021 and Full Year 2021 Financial Results and Corporate Update
-
Spectrum Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results and Provide Corporate Update
-
Spectrum Pharmaceuticals Appoints Juhyun Lim of Hanmi Pharmaceutical to Board of Directors
-
Spectrum Pharmaceuticals Presents Positive Data for Poziotinib in First-line NSCLC Patients with HER2 Exon 20 Insertion Mutations
Back to SPPI Stock Lookup
